ArticleAnnals of translational medicine2021

The safety and efficacy of neoadjuvant programmed death 1 inhibitor therapy with surgical resection in stage IIIA non-small cell lung cancer.

Jiangfeng Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.